Daewoong Eyes Entry Into China Stem Cell Sector
This article was originally published in PharmAsia News
Executive Summary
After a licensing deal with stem cell company Kang Stem Biotech a few months ago, Daewoong Pharm is now accelerating its efforts to expand in the sector internationally through a deal for the Chinese market. To tackle difficulties faced by foreign pharma firms in gaining regulatory approvals in China, the two South Korean companies will involve the Chinese government in the project.